Pharmacological Management of Obesity

Join our CE course for Nurses and NPs on the Pharmacological Management of Obesity to gain a comprehensive understanding of the multifactorial nature of obesity and its treatment. This course explores the definitions, epidemiology, and risk factors associated with obesity, including behavioral, environmental, and genetic influences. Learners will explore the pathophysiology of obesity, focusing on energy balance, hormonal dysregulation, and metabolic pathways. The course highlights the diagnostic criteria, such as BMI, waist circumference, and comorbid conditions, that inform clinical decision-making.

Participants will review FDA-approved pharmacological options for obesity management, including Orlistat, Liraglutide, Phentermine/Topiramate, and Naltrexone/Bupropion (Contrave), evaluating their mechanisms of action, efficacy, indications, and side effects. The course emphasizes comprehensive obesity care by integrating lifestyle interventions like diet, physical activity, behavioral counseling, and pharmacotherapy. Nurses and NPs will gain essential skills for patient-centered communication, adherence strategies, monitoring, and safely titrating medications. This course equips clinicians to support sustainable weight loss outcomes and improve patient quality of life while addressing the long-term health risks associated with obesity, including cardiovascular disease, type 2 diabetes, and certain cancers.

Educational Objectives

• Define obesity and understand its epidemiology, diagnostic criteria, and major risk factors, including genetics and lifestyle.
• Describe the pathophysiology of obesity, including the role of energy imbalance, hormone regulation, and metabolic dysfunction.
• Identify common health complications associated with obesity, such as type 2 diabetes, cardiovascular disease, and obstructive sleep apnea.
• Review FDA-approved pharmacologic agents used for obesity treatment, such as Orlistat, Liraglutide, Phentermine/Topiramate, and Contrave.
• Explain safety considerations, contraindications, and monitoring parameters when prescribing anti-obesity medications.
• Integrate pharmacological treatments with behavioral and lifestyle interventions to create individualized care plans.

Who Should Do This Course

This course is designed for Registered Nurses (RNs) and Nurse Practitioners (NPs) involved in primary care, endocrinology, bariatric care, internal medicine, and preventive healthcare. It fulfills the state-required mandatory topic(s) credit requirements for license renewal:

• Advanced Pharmacology – Nursing: Ohio, Alaska
• Pharmacotherapeutics – Nursing: Hawaii, Louisiana, Oklahoma, West Virginia, Connecticut, Arkansas, Illinois, Nebraska, South Carolina, Texas, Washington, Wisconsin
• Pharmacology – Nursing: Alabama, Indiana

Did You Know?

• According to the CDC, over 42% of U.S. adults were classified as obese in 2020, highlighting the growing prevalence of obesity in healthcare.
• Weight loss of just 5-10% of body weight has been shown to significantly improve blood pressure, cholesterol, and glucose control.
• Liraglutide, a GLP-1 receptor agonist, has shown sustained weight loss benefits when combined with lifestyle modification.
• Orlistat is the only FDA-approved over-the-counter medication for weight loss, acting by reducing dietary fat absorption by 30%.
• Pharmacotherapy is recommended for patients with a BMI >=30 kg/m² or >=27 kg/m² with obesity-related comorbidities.